risperidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 5 Diseases   67 Trials   67 Trials   4266 News 


«12...1314151617181920212223...6364»
  • ||||||||||  meloxicam / Generic mfg., risperidone / Generic mfg., paracetamol / Generic mfg.
    Journal:  Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain. (Pubmed Central) -  May 17, 2022   
    This suggests that COX inhibition is only a partial explanation of the increased analgesic potency of paracetamol and meloxicam since the effects of NSAIDs in the CNS are mediated by multiple mechanisms. These results indicate that the combination of risperidone with paracetamol or meloxicam could be a new and effective alternative for the management of inflammatory pain.
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka, Caplyta (lumateperone) - Intra / Cellular Therapies
    Retrospective data, Journal:  Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  May 12, 2022   
    Second-generation antipsychotics do not only differ in their propensity to produce weight gain, but also in the shapes of their dose-response curves. This information is important for dosing decisions in clinical practice.
  • ||||||||||  Journal:  Precision psychiatry: The complexity of personalizing antipsychotic dosing. (Pubmed Central) -  May 10, 2022   
    This short communication focuses on personalized dosing of three oral antipsychotics (clozapine, risperidone and paliperidone) and presents their maintenance dosing in a table which provides dose-correction factors generated by pharmacokinetic studies...Fluoxetine co-prescription may require one fourth the risperidone maintenance dose...Although not well studied, two groups may need higher doses of oral paliperidone: Koreans may need 1.5 times higher doses while those taking carbamazepine may need 3 times higher paliperidone maintenance doses. Precision dosing in psychiatry requires using blood levels of individuals.
  • ||||||||||  risperidone / Generic mfg.
    Journal:  Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. (Pubmed Central) -  May 6, 2022   
    We did not identify shared loci or genes between GWAS and WES, but association signals tended to cluster into the GPCR gene family and GPCR signaling pathway, which may play an important role in the treatment response etiology. This study may provide a research paradigm for pharmacogenomic research, and these data provide a promising illustration of our potential to identify genetic variants underlying antipsychotic responses and may ultimately facilitate precision medicine in schizophrenia.
  • ||||||||||  Review, Journal:  Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. (Pubmed Central) -  May 6, 2022   
    While the majority of data is based on naturalistic studies investigating risperidone LAIs or paliperidone palmitate, LAIs may be an effective treatment for early psychosis patients in terms of adherence, relapse reduction, and symptom improvements. There is still a need to conduct more high quality RCTs that investigate the efficacy of different LAI formulations in early psychosis patients.
  • ||||||||||  risperidone / Generic mfg., midazolam hydrochloride / Generic mfg., omeprazole / Generic mfg.
    Journal:  INTERSYSTEM EXTRAPOLATION FACTORS (ISEF) ARE SUBSTRATE-DEPENDENT FOR CYP3A4: IMPACT ON CYTOCHROME P450 REACTION PHENOTYPING. (Pubmed Central) -  May 6, 2022   
    For risperidone, estimated f values for CYP3A4 and CYP2D6 ranged from 0.87-0.98 and 0.02-0.13, respectively, as compared with in vivo values of 0.36 (CYP3A4) and 0.63-0.88 (CYP2D6), showing that the importance of CYP3A4 was overestimated, and the importance of CYP2D6 underestimated...The present data shows that ISEF values for cytochrome P4503A4 vary with the substrate. This can lead to variable and erroneous prediction of f.
  • ||||||||||  Risperdal Consta (risperidone depot formulation) / J&J
    PK/PD data, Journal:  Model for Long Acting Injectables (Depot Formulation) Based on Pharmacokinetics and Physical Chemical Properties. (Pubmed Central) -  May 6, 2022   
    The PK predictions for several drugs such as estradiol, risperidone, medroxyprogesterone acetate (MPA), and ziprasidone showed how these predictions can guide scientists to target specific depot doses and release rates into the depot formulation...The framework, prediction tools, and depot map will reduce the need for semi-empirical formulation work and preclinical studies to design depot formulations. Graphical Abstract.
  • ||||||||||  risperidone / Generic mfg.
    Journal:  Risperidone on apomorphine-induced stereotyped behavior and auditory sensory gating in rhesus monkeys. (Pubmed Central) -  May 6, 2022   
    Administering of risperidone (0.1mg/kg, s.c.) 30min before apomorphine treatment significantly restricted the T/C ratio to 0.571 ± 0.0886 (n = 4), compared to the T/C ratio in the vehicle-administered control group. The above results demonstrate, not only behaviorally but also electrophysiologically, the ameliorating effect of risperidone on the induction of schizophrenia-like symptoms by apomorphine in non-human primates.
  • ||||||||||  risperidone / Generic mfg.
    My Stomach is Growling at Me: Cenesthopathy as Auditory Visceral Hallucinations () -  May 6, 2022 - Abstract #SOBP2022SOBP_319;    
    Alternatively, this could not be a hallucination at all but rather a colloquial description of the perception of hunger. Peradventure, this could have been borborygmi emanating from the stomach, which the patient heard, and either misinterpreted as a hallucination or was attempting to express as a trope.
  • ||||||||||  MK-8189 / Merck (MSD)
    MK-8189, a Novel PDE10A Inhibitor for the Treatment of Schizophrenia (Palomino Ballroom 4-10) -  May 6, 2022 - Abstract #ASCP2022ASCP_112;    
    P2a, P2b
    These findings suggest that PDE10A inhibition via MK-8189 could represent a new treatment approach for schizophrenia. Based on the signal detected in the phase 2a study, a phase 2b study (NCT04624243) is underway to evaluate a broader dose range of MK-8189.
  • ||||||||||  VMAT2 inhibitor / Neurocrine
    Synergy between VMAT2 Inhibitors and Antipsychotics in Animal Models of Schizophrenia (Palomino Ballroom 4-10) -  May 6, 2022 - Abstract #ASCP2022ASCP_100;    
    CAR suppression increased when subthreshold doses of [+]-α-HTBZ and risperidone were combined (range, 6.5-7.1 escapes), and the results were comparable to the effects at threshold doses for [+]-α-HTBZ alone (4.8-11.4 escapes [0.3 mg/kg]) and risperidone alone (7.2-8.0 escapes [0.3 mg/kg]). This synergistic effect was not due to a drug-drug interaction, as the combination of drugs did not significantly affect the plasma concentration of either agent.
  • ||||||||||  MK-8189 / Merck (MSD)
    MK-8189, a Novel PDE10A Inhibitor for the Treatment of Schizophrenia (Salon A-E) -  May 6, 2022 - Abstract #ASCP2022ASCP_28;    
    P2a, P2b
    These findings suggest that PDE10A inhibition via MK-8189 could represent a new treatment approach for schizophrenia. Based on the signal detected in the phase 2a study, a phase 2b study (NCT04624243) is underway to evaluate a broader dose range of MK-8189.
  • ||||||||||  risperidone / Generic mfg.
    Journal:  Deciphering Risperidone-Induced Lipogenesis by Network Pharmacology and Molecular Validation. (Pubmed Central) -  May 6, 2022   
    Intersecting analysis, molecular docking, and pathway validation analysis showed that risperidone influences the adipocytokine signaling pathway by targeting MAPK14 (mitogen-activated protein kinase 14), MAPK8 (mitogen-activated protein kinase 8), and RXRA (retinoic acid receptor RXR-alpha), thereby inhibiting long-chain fatty acid β-oxidation by decreasing STAT3 (signal transducer and activator of transcription 3) expression and phosphorylation. Risperidone increases adipocyte lipid accumulation by plausibly inhibiting long-chain fatty acid β-oxidation through targeting MAPK14 and MAPK8.
  • ||||||||||  Lybalvi (olanzapine/samidorphan) / Alkermes, Caplyta (lumateperone) - Intra / Cellular Therapies
    8211: Clinical Update on Managing Schizophrenia: Drugs and Other Treatments ([VIRTUAL]) -  May 5, 2022 - Abstract #APA2022APA_1136;    
    The clinical implications of new research on non-pharmacologic somatic treatments including aerobic exercise, transcranial magnetic stimulation, and electroconvulsive therapy will be discussed. Finally, there will be a discussion of new drugs for schizophrenia that are in Phase 3 trials.
  • ||||||||||  risperidone / Generic mfg., olanzapine / Generic mfg.
    Synergy Between VMAT2 Inhibitors and Antipsychotics in Animal Models of Schizophrenia () -  May 5, 2022 - Abstract #APA2022APA_1065;    
    CAR suppression increased when subthreshold doses of [+]-a-HTBZ and risperidone were combined (range, 6.5-7.1 escapes), and the results were comparable to the effects at threshold doses for [+]-a-HTBZ alone (4.8-11.4 escapes [0.3 mg/kg]) and risperidone alone (7.2-8.0 escapes [0.3 mg/kg]). This synergistic effect was not due to a drug-drug interaction, as the combination of drugs did not significantly affect the plasma concentration of either agent.
  • ||||||||||  risperidone / Generic mfg., olanzapine / Generic mfg., clozapine / Generic mfg.
    Racial and Gender Disparities in Antipsychotic Prescribing () -  May 5, 2022 - Abstract #APA2022APA_1031;    
    Similar racial disparities were reported in the past, when there were far fewer atypical agents available, but prescribing disparities by sex to not appear to have been reported previously. A racial disparity in clozapine prescribing, reported in a previous study, was not seen in this data set.
  • ||||||||||  Psychiatry and Prolactin—a Review of Literature () -  May 5, 2022 - Abstract #APA2022APA_1023;    
    The ranking in order of Hyperprolactinemia presented by these authors: Paliperidone > Risperidone > Lurasidone > Ziprasidone > Iloperidone > Olanzapine > Asenapine > Placebo > Quetiapine > Aripiprazole...Cabergoline is preferable to Bromocriptine...Another type of treatment: Alternative and symptomatic management can also be attempted. Estrogens or testosterone for hypogonadism and/or decreased BMD, PDE5 inhibitors for erectile dysfunction, promoting healthy diet and physical exercise, avoiding tobacco and alcohol, for amenorrhea>6 months OCPs can be given to prevent osteoporosis, If low Vitamin D levels, then supplementation etc Psychiatrists need to work corroboratively with other specialties of Medicine and keep abreast of recent evidence base to manage this problem.
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    High Doses of Second-Generation Long-Acting Antipsychotics in Patients With Severe Resistant Schizophrenia. a Six-Year Mirror-Image Study () -  May 5, 2022 - Abstract #APA2022APA_753;    
    Conclusions Risperidone LAI, Paliperidone Palmitate and Aripiprazol once-monthly, at high doses, improved treatment adherence and outcomes (hospitalizations, suicide attempts, clinical severity, disability) of patients with severe resistant schizophrenia, with good tolerability, helping them to achieve clinical stabilization and better functioning. Therefore, we suggest that, in some illness critical conditions, high doses of SGA LAIs could represent an alternative to clozapine.
  • ||||||||||  risperidone / Generic mfg.
    Half a Century Surviving With Shrapnel Within the Brain () -  May 5, 2022 - Abstract #APA2022APA_752;    
    She is non-diabetic, non hypertensive non anemic or icteric. She was advised on Risperidone 2mg daily at night, and her psychosis was controlled.
  • ||||||||||  Too Much Too Little Too Late: Chronic Hypercalcemia and Sudden Antidepressant Withdrawal as Risk Factors for Late Onset Mania () -  May 5, 2022 - Abstract #APA2022APA_701;    
    However, due to decreased need for sleep of two to three hours a night, patient was switched to olanzapine 10 mg with lorazepam 2 mg at bedtime...Without a holistic approach, a patient’s manic symptoms may remain refractory to antipsychotic treatment since the underlying cause may be left unaddressed. In this poster, we discuss the laboratory algorithm for assessing hypercalcemia as well as abrupt SSRI dose decreases or discontinuation as risk factors for late onset mania.
  • ||||||||||  risperidone / Generic mfg.
    Time Consistent Oculogyric Crisis in a 13-Year-Old Female on Risperidone With COVID-19 Infection () -  May 5, 2022 - Abstract #APA2022APA_693;    
    To the best of our knowledge this is the first such case described in children. It elucidates the importance of medical providers’ ability to recognize and manage acute dystonia in children with neurodevelopmental disorders who have an increased sensitivity to antipsychotics especially as COVID-19 related hospitalizations are increasing among this age group.
  • ||||||||||  olanzapine / Generic mfg., methamphetamine / Generic mfg.
    The Use of Olanzapine as Preferred Treatment Choice for Methamphetamine Associated Psychosis () -  May 5, 2022 - Abstract #APA2022APA_690;    
    Olanzapine can help in the treatment of methamphetamine-associated psychosis and can be considered as the first-line therapy. Research is further needed with a higher pool of candidates in the future to compare the efficacy and tolerability of different typical and atypical antipsychotics.
  • ||||||||||  clozapine / Generic mfg.
    Refractory Mania Post-COVID-19 Infection Responsive to Clozapine () -  May 5, 2022 - Abstract #APA2022APA_623;    
    Background: Currently, there is robust evidence for the treatment of mania with lithium, valproate, carbamazepine and seven FDA approved antipsychotic medications: aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone (1). There is also evidence for the use of clozapine and electroconvulsive therapy for treatment-refractory mania Speaker(s) Poster Presenter Emma Charlotte Cooper, MD View Profile Co-Author Vedang S. Uttarwar, MD View Profile Co-Author Alexis Seegan, MD View Profile
  • ||||||||||  risperidone / Generic mfg., olanzapine / Generic mfg.
    Psychotic Presentation of Anti-Hu Encephalitis: A Case Series With Review of Literature () -  May 5, 2022 - Abstract #APA2022APA_612;    
    Psychotic symptoms are seldom reported in the literature and cases like the ones presented here emphasize the importance of a full medical work-up for first episode psychotic symptoms as well as a wide differential. Given the increased association between PNS and psychiatric illness, more emphasis and further research is warranted.